arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Cue Biopharma, Inc.

CUE

$27.21 ▲ +0.20 (+0.72%) at close

10 Visible periods

31 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Cue Biopharma, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.6B

Dividend Yield —

Revenue Growth 195.7% ↗

Op. Margin -96.7% ↗

ROIC -79.4% ↗

FCF / Share $-0.23 ↗

Trailing P/E —

Price / Book 99.5x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

10-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$27.47M

↑ +195.7% —

Net Income Profit after all expenses

$-26.60M

↑ +34.6% —

Operating Margin Operating profit as % of sales

-96.7%

↑ +78.4% 2th

FCF / Share Free cash flow per share

$-0.23

↑ +64.3% —

Long-Term Debt Long-term obligations

$0.00

↓ -100.0% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile
Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑

Returns ↓

Financial Health ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Revenue Growth YoY (%)	195.7% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+2347%)	69.2% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+765%)	340.9% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+4161%)	-91.7% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1246%)	373.7% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+4571%)	-8.8% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-210%)	202.7% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+2433%)	—	—	—
EPS Growth YoY (%)	61.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	35.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	25.5% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-5.7% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	34.6% Excellent ↑ Excellent Improving Year-over-year change in net income	19.8% Good ↑ Good Improving Year-over-year change in net income	4.3% Caution ↑ Caution Improving Year-over-year change in net income	-20.0% Weak ↓ Weak Declining Year-over-year change in net income	1.4% Caution ↑ Caution Improving Year-over-year change in net income	-22.0% Weak ↑ Weak Improving Year-over-year change in net income	5.9% Fair Fair Year-over-year change in net income	-67.8% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	64.3% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	26.0% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	25.8% Excellent Excellent Year-over-year change in free cash flow	7.3% Fair Fair Year-over-year change in free cash flow	—	—	—	—	—	—
Revenue CAGR 3Y (%)	180.4% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	-14.7% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	20.3% Excellent ↓ Excellent Declining Compound annual revenue growth over 3 years	-28.9% Weak Weak Compound annual revenue growth over 3 years	135.6% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—
Revenue CAGR 5Y (%)	54.2% Excellent ↑ Excellent Improving Compound annual revenue growth over 5 years	21.8% Excellent Excellent Compound annual revenue growth over 5 years	36.9% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Operating Margin (%) (%)	-96.7% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-744%)	-446.9% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3079%)	—	—	-292.6% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2050%)	—	—	—	—	—
Effective Tax Rate (%) (%)	—	—	—	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.5% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-2.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
Profit Margin (%) (%)	-96.9% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-907%)	-438.0% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3750%)	—	—	-295.6% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2563%)	—	—	—	—	—
FCF Margin (%) (%)	-79.6% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-391.9% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	-266.0% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—
FCF / Net Income (x)	0.82x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.79x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.79x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.84x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.73x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.57x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Return on Invested Capital (%)	-79.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-187.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-100.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-72.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-67.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-57.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-68.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-116.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-29.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-62.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-128.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-84.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-58.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-52.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-45.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-51.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-85.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	-34.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-100.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-771%)	-232.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1650%)	-136.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1012%)	-80.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-638%)	-67.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-550%)	-56.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-478%)	-67.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-548%)	-114.7% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-865%)	-37.7% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-351%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Debt to Equity (x)	—	0.00x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	0.11x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-82%)	0.12x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-80%)	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	—	—	—	—	—
Interest Coverage (x)	-265.52x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-415.00x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-401.15x Weak Weak Operating income divided by interest expense Optimal: > 5x	-93.32x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—	—
Net Debt (USD)	$-27.14M	$-22.42M	$-44.48M	$-43.54M	$-64.37M	$-74.87M	$-44.29M	$-20.80M	—	—
Debt / EBITDA (x)	—	-0.00x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.08x Excellent → Excellent Stable Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.15x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.00x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Revenue per Share (USD)	$0.29	$0.16	$0.12	$0.03	$0.48	—	—	—	—	—
Basic EPS, GAAP (USD)	$-0.28	$-0.72	$-1.11	$-1.49	$-1.41	—	—	—	—	—
Free Cash Flow per Share (USD)	$-0.23	$-0.65	$-0.87	$-1.18	$-1.27	—	—	—	—	—
Book Value per Share (USD)	$0.27	$0.28	$0.86	$1.53	$2.03	$2.60	$2.05	$1.64	$3.17	—
Tangible Book Value per Share (USD)	$0.27	$0.28	$0.86	$1.53	$2.03	$2.60	$2.05	$1.64	$3.17	—
Basic Weighted Avg Shares (shares)	94.73M	56.33M	45.75M	35.65M	31.29M	—	—	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Working Capital (USD)	$23.49M	$11.45M	$34.37M	$65.64M	$55.68M	$71.21M	$49.37M	$34.39M	$59.72M	—
LT Debt (USD)	—	$0.00	$4.00M	$8.00M	$0.00	—	—	—	—	—
Total Equity (USD)	$26.43M	$17.50M	$37.09M	$65.68M	$65.49M	$78.91M	$54.58M	$33.97M	$61.61M	$15.17M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Sales/Revenue/Turnover (USD)	$27.47M	$9.29M	$5.49M	$1.25M	$14.94M	$3.15M	$3.46M	$1.14M	—	—
Depreciation Expense (USD)	$336.00K	$385.00K	$545.00K	$830.58K	$909.11K	$780.53K	$799.11K	$760.01K	$419.57K	—
Net Income, GAAP (USD)	$-26.60M	$-40.67M	$-50.73M	$-53.01M	$-44.16M	$-44.78M	$-36.70M	$-38.98M	$-23.23M	—
Operating Cash Flow (USD)	$-21.69M	$-36.33M	$-39.96M	$-41.81M	$-38.84M	$-32.49M	$-30.80M	$-26.41M	$-12.14M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 38 quarters

Cue Biopharma, Inc.

Analytical Summary

10-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CUE with peers